Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06059664 · ClinicalTrials.gov registry record · Phase 2

The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study

A Phase 2 study of Kidney Transplant; Complications, sponsored by University of North Carolina, Chapel Hill.

Recruiting
Registry status
Phase 2
Development phase
150
Enrollment target
1
Study location

NCT06059664 is a Phase 2 study of Kidney Transplant; Complications that is actively recruiting participants, run by University of North Carolina, Chapel Hill. The registered enrollment target is 150 participants, above the 114-participant average among 19 other Kidney Transplant; Complications trials with a reported enrollment target (32% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06059664, a Phase 2 study of Kidney Transplant; Complications, is actively recruiting participants, sponsored by University of North Carolina, Chapel Hill.

RECRUITING
Registry status
Phase 2
Development phase
150 participants
Enrollment target
1
Study location

Study Summary

EFFEKTOR is a vanguard, multicenter, phase 2 randomized, double blinded, placebo controlled clinical trial to determine the feasibility, tolerability, safety, and efficacy of finerenone in kidney transplant recipients (KTRs). One hundred fifty (150) KTRs will be randomized in a 2:1 ratio of finerenone to placebo, with two embedded substudies: (i) a kidney biopsy substudy in 50 participants who undergo a research kidney biopsy prior to randomization and at the end of active treatment; and (ii) a functional MRI (fMRI) substudy in 50 participants who undergo fMRI prior to randomization and at the end of active treatment.

Conditions Studied

Kidney Transplant; Complications

Interventions

  • DRUG Placebo
  • DRUG Finerenone Oral Tablet

Study Locations (1)

North Carolina

  • UNC Eastowne Kidney Transplant Clinic - Chapel Hill

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2024-04-23
Est. Completion 2027-09-30
Phase Phase 2

Sponsor

University of North Carolina, Chapel Hill

1,109 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06059664

The ClinicalTrials.gov registry entry for NCT06059664 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 114-participant average among 19 other Kidney Transplant; Complications trials with a reported enrollment target (32% higher). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Kidney Transplant; Complications appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06059664 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT06059664 about?

NCT06059664 is a clinical study titled "The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study". EFFEKTOR is a vanguard, multicenter, phase 2 randomized, double blinded, placebo controlled clinical trial to determine the feasibility, tolerability, safety, and efficacy of finerenone in kidney transplant recipients (KTRs). One hundred fifty (150) KTRs will be randomized in a 2:1 ratio of finereno...

What is the current status of trial NCT06059664?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2024-04-23. Estimated completion is 2027-09-30.

What conditions does trial NCT06059664 study?

This clinical trial studies the following conditions: Kidney Transplant; Complications.

What interventions are being tested in trial NCT06059664?

The interventions under investigation include: Placebo (DRUG), Finerenone Oral Tablet (DRUG).

Who is sponsoring clinical trial NCT06059664?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06059664 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Kidney Transplant; Complications

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Kidney Transplant; Complications

All registered trials for this condition

North Carolina

All trials with a study site in North Carolina

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.